PREVENTION AND TREATMENT OF ROTAVIRUS DIARRHOEA

• US 20120107279A1
• Filed: 11/27/2009
• Published: 05/03/2012
• Est. Priority Date: 12/19/2008
• Status: Abandoned Application

• Current Assignee: Nestec SA (Nestle SA)
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Arigoni, Fabrizio, Bruessow, Harald, Cavadini, Christoph, Page, Nicolas
• Application Number:
  US13/140,546
• Publication Number:
  US 20120107279A1
• Time in Patent Office: Days
• US Class Current: 424/93.4
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/10 Preserving against microbes
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2200/3202 Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A23V 2250/156 Mineral combination undefined extract A23V2250/1638
• CPC Class Codes: A23V 2250/1872 Linoleic acid
• CPC Class Codes: A23V 2250/1874 Linolenic acid
• CPC Class Codes: A23V 2250/612 Lactose
• CPC Class Codes: A23V 2250/70 Vitamins
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61P 1/12 Antidiarrhoeals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/01 Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Abstract

This invention relates to Bifidobacterium breve CNCM I-3865, to a composition comprising Bifidobacterium breve CNCM I-3865 and to the use of Bifidobacterium breve CNCM I-3865 in the prevention or treatment of rotavirus diarrhoea. prevention and treatment of rotavirus diarrhoea

Claims

1. Bifidobacterium breve CNCM I-3865.

2. A composition comprising Bifidobacterium breve CNCM I-3865.

3. A composition according to claim 2 which is in a form selected from the group consisting of an infant formula, a follow-on formula and a growing-up milk.

4. A composition according to claim 3 comprising Bifidobacterium breve CNCM I-3865 in an amount equivalent to between 10e3 and 10e12 cfu/g on a dry weight basis.

5. A composition according to claim 2 comprises Bifidobacterium breve CNCM I-3865 in an amount equivalent to between 10e7 and 10e12 cfu/g.

6. A composition according to claim 2 comprising at least one prebiotic in an amount of from 0.3 to 6% by weight of the composition.

7. A composition according to claim 2 which is a supplement and comprises from 10⁴ to 10¹² cfu of Bifidobacterium breve CNCM I-3865 per unit dose.

8. A method for manufacturing a medicament or therapeutic nutritional composition comprising the steps of using Bifidobacterium breve CNCM I-3865 to prepare the medicament or composition.

9. A method for preventing or treating rotavirus diarrhea comprising the step of administering a therapeutically effective amount of Bifidobacterium breve CNCM I-3865 to an individual having same.

11. A composition according to claim 9 which is in a form selected from the group consisting of an infant formula, a follow-on formula and a growing-up milk.

12. A composition according to claim 11 comprising Bifidobacterium breve CNCM I-3865 in an amount equivalent to between 10e3 and 10e12 cfu/g on a dry weight basis.

15. A composition according to claim 9 comprising at least one prebiotic in an amount of from 0.3 to 6% by weight of the composition.

16. A composition according to claim 11 comprising at least one prebiotic in an amount of from 0.3 to 6% by weight of the composition.

10. A method for preventing rotavirus diarrhea comprising the step of administering a therapeutically effective amount of a composition comprising Bifidobacterium breve CNCM I-3865 to an individual at risk of same.

13. A composition according to claim 10 which is in a form selected from the group consisting of an infant formula, a follow-on formula and a growing-up milk.

14. A composition according to claim 13 comprising Bifidobacterium breve CNCM I-3865 in an amount equivalent to between 10e3 and 10e12 cfu/g on a dry weight basis.